JP2022502010A5 - - Google Patents
Info
- Publication number
- JP2022502010A5 JP2022502010A5 JP2021512587A JP2021512587A JP2022502010A5 JP 2022502010 A5 JP2022502010 A5 JP 2022502010A5 JP 2021512587 A JP2021512587 A JP 2021512587A JP 2021512587 A JP2021512587 A JP 2021512587A JP 2022502010 A5 JP2022502010 A5 JP 2022502010A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- determination region
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024083730A JP7777183B2 (ja) | 2018-09-28 | 2024-05-23 | Cd3およびcd137に結合することができるが、同時には結合しない、抗原結合分子 |
| JP2025194883A JP2026021604A (ja) | 2018-09-28 | 2025-11-14 | Cd3およびcd137に結合することができるが、同時には結合しない、抗原結合分子 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018185120 | 2018-09-28 | ||
| JP2018185120 | 2018-09-28 | ||
| JP2019104308 | 2019-06-04 | ||
| JP2019104308 | 2019-06-04 | ||
| PCT/JP2019/038138 WO2020067419A1 (en) | 2018-09-28 | 2019-09-27 | Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024083730A Division JP7777183B2 (ja) | 2018-09-28 | 2024-05-23 | Cd3およびcd137に結合することができるが、同時には結合しない、抗原結合分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022502010A JP2022502010A (ja) | 2022-01-11 |
| JP2022502010A5 true JP2022502010A5 (cg-RX-API-DMAC7.html) | 2022-09-13 |
| JP7519990B2 JP7519990B2 (ja) | 2024-07-22 |
Family
ID=69950671
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021512587A Active JP7519990B2 (ja) | 2018-09-28 | 2019-09-27 | Cd3およびcd137に結合することができるが、同時には結合しない、抗原結合分子 |
| JP2024083730A Active JP7777183B2 (ja) | 2018-09-28 | 2024-05-23 | Cd3およびcd137に結合することができるが、同時には結合しない、抗原結合分子 |
| JP2025194883A Pending JP2026021604A (ja) | 2018-09-28 | 2025-11-14 | Cd3およびcd137に結合することができるが、同時には結合しない、抗原結合分子 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024083730A Active JP7777183B2 (ja) | 2018-09-28 | 2024-05-23 | Cd3およびcd137に結合することができるが、同時には結合しない、抗原結合分子 |
| JP2025194883A Pending JP2026021604A (ja) | 2018-09-28 | 2025-11-14 | Cd3およびcd137に結合することができるが、同時には結合しない、抗原結合分子 |
Country Status (19)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4310191A3 (en) | 2012-06-14 | 2024-05-15 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing modified fc region |
| CA2929044A1 (en) | 2013-11-11 | 2015-05-14 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing modified antibody variable region |
| US11154615B2 (en) | 2014-11-11 | 2021-10-26 | Chugai Seiyaku Kabushiki Kaisha | Library of antigen-binding molecules including modified antibody variable region |
| JP7357616B2 (ja) | 2017-12-05 | 2023-10-06 | 中外製薬株式会社 | Cd3およびcd137に結合する改変された抗体可変領域を含む抗原結合分子 |
| JP7314146B2 (ja) | 2017-12-28 | 2023-07-25 | 中外製薬株式会社 | 細胞傷害誘導治療剤 |
| US12435137B2 (en) | 2018-08-03 | 2025-10-07 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing two antigen-binding domains that are linked to each other |
| JP2022501325A (ja) | 2018-09-28 | 2022-01-06 | 中外製薬株式会社 | 改変された抗体可変領域を含む抗原結合分子 |
| JP7359864B2 (ja) | 2019-07-10 | 2023-10-11 | 中外製薬株式会社 | クローディン6結合分子およびその使用 |
| JP7736688B2 (ja) * | 2020-03-31 | 2025-09-09 | 中外製薬株式会社 | 多重特異性抗原結合分子を製造するための方法 |
| AR121692A1 (es) * | 2020-03-31 | 2022-06-29 | Chugai Pharmaceutical Co Ltd | Moléculas de unión a antígeno multiespecíficas activadoras de la inmunidad y usos de estas |
| CA3173587A1 (en) | 2020-03-31 | 2021-10-07 | Chugai Seiyaku Kabushiki-Kaisha | Dll3-targeting multispecific antigen-binding molecules and uses thereof |
| WO2023036043A1 (zh) * | 2021-09-09 | 2023-03-16 | 广东东阳光药业有限公司 | 抗癌结合分子及其应用 |
| JP7470760B2 (ja) * | 2021-09-29 | 2024-04-18 | 中外製薬株式会社 | がんの治療に用いるための細胞傷害誘導治療剤 |
| JP7557922B2 (ja) | 2021-09-29 | 2024-09-30 | 中外製薬株式会社 | Dll3標的多重特異性抗原結合分子の使用 |
| JPWO2023053282A1 (cg-RX-API-DMAC7.html) * | 2021-09-29 | 2023-04-06 | ||
| WO2023053272A1 (en) * | 2021-09-29 | 2023-04-06 | Chugai Seiyaku Kabushiki Kaisha | Uses of dll3-targeting multispecific antigen-binding molecules |
| EP4524248A4 (en) * | 2022-05-12 | 2026-07-01 | Astellas Pharma Inc | MULTISPECIFIC ANTI-TAA AND ANTI-CD3 ANTIBODY |
| WO2024114676A1 (zh) * | 2022-11-29 | 2024-06-06 | 江苏恒瑞医药股份有限公司 | Cldn18.2/4-1bb结合蛋白及其医药用途 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル,インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| EP0656941B1 (en) | 1992-03-24 | 2005-06-01 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| CA2177367A1 (en) | 1993-12-03 | 1995-06-08 | Andrew David Griffiths | Recombinant binding proteins and peptides |
| DE4419399C1 (de) | 1994-06-03 | 1995-03-09 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von heterologen bispezifischen Antikörpern |
| ATE340590T1 (de) | 1994-07-13 | 2006-10-15 | Chugai Pharmaceutical Co Ltd | Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| ES2299244T3 (es) | 1998-05-13 | 2008-05-16 | Domantis Limited | Sistema de exposicion de fagos para la seleccion de proteinas correctamente plegadas. |
| AU1219000A (en) | 1998-10-22 | 2000-05-08 | Regents Of The University Of California, The | Functionally assembled antigen-specific intact recombinant antibody and a methodfor production thereof |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| EP3342782B1 (en) | 2004-07-15 | 2022-08-17 | Xencor, Inc. | Optimized fc variants |
| US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| WO2006132352A1 (ja) | 2005-06-10 | 2006-12-14 | Chugai Seiyaku Kabushiki Kaisha | sc(Fv)2を含有する医薬組成物 |
| JP5144499B2 (ja) | 2006-03-31 | 2013-02-13 | 中外製薬株式会社 | 二重特異性抗体を精製するための抗体改変方法 |
| EP2626372B1 (en) | 2007-03-29 | 2018-03-21 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| EP2144931A2 (en) | 2007-04-04 | 2010-01-20 | The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services | Monoclonal antibodies against dengue and other viruses with deletion in fc region |
| ES2687808T3 (es) | 2007-09-26 | 2018-10-29 | Chugai Seiyaku Kabushiki Kaisha | Región constante de anticuerpo modificado |
| KR101616758B1 (ko) | 2007-12-26 | 2016-04-29 | 젠코어 인코포레이티드 | FcRn에 대한 변경된 결합성을 갖는 Fc 변이체 |
| TW201920257A (zh) | 2008-04-11 | 2019-06-01 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗原結合分子 |
| EP2283358B1 (en) | 2008-04-29 | 2015-04-22 | Immunexcite, Inc. | Immunomodulating compositions and methods of use thereof |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| EP2543730B1 (en) | 2010-03-04 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| WO2012023053A2 (en) | 2010-08-16 | 2012-02-23 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| CN105859889B (zh) * | 2010-11-17 | 2020-01-07 | 中外制药株式会社 | 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子 |
| TWI736437B (zh) | 2010-11-30 | 2021-08-11 | 日商中外製藥股份有限公司 | 細胞傷害誘導治療劑 |
| US20140080153A1 (en) | 2011-01-07 | 2014-03-20 | Chugai Seiyaku Kabushiki Kaisha | Method for improving physical properties of antibody |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| WO2013180200A1 (ja) | 2012-05-30 | 2013-12-05 | 中外製薬株式会社 | 標的組織特異的抗原結合分子 |
| EP2948475A2 (en) * | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
| MX2016003617A (es) | 2013-09-30 | 2016-07-21 | Chugai Pharmaceutical Co Ltd | Metodo para producir molecula de enlace al antigeno usando fago auxiliar modificado. |
| CA2929044A1 (en) * | 2013-11-11 | 2015-05-14 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing modified antibody variable region |
| MX380176B (es) * | 2014-04-07 | 2025-03-12 | Chugai Pharmaceutical Co Ltd | Molecula ligada a antigeno inmunoactivada. |
| US11154615B2 (en) | 2014-11-11 | 2021-10-26 | Chugai Seiyaku Kabushiki Kaisha | Library of antigen-binding molecules including modified antibody variable region |
| EP3305322A4 (en) * | 2015-06-05 | 2018-12-26 | Chugai Seiyaku Kabushiki Kaisha | Combined use of immune activators |
| KR102692708B1 (ko) * | 2016-12-20 | 2024-08-07 | 에프. 호프만-라 로슈 아게 | 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법 |
| JP7357616B2 (ja) * | 2017-12-05 | 2023-10-06 | 中外製薬株式会社 | Cd3およびcd137に結合する改変された抗体可変領域を含む抗原結合分子 |
-
2019
- 2019-09-27 KR KR1020217012569A patent/KR20210068079A/ko not_active Withdrawn
- 2019-09-27 WO PCT/JP2019/038138 patent/WO2020067419A1/en not_active Ceased
- 2019-09-27 SG SG11202101912UA patent/SG11202101912UA/en unknown
- 2019-09-27 CA CA3114154A patent/CA3114154A1/en active Pending
- 2019-09-27 US US17/272,972 patent/US20210388087A1/en active Pending
- 2019-09-27 MA MA053742A patent/MA53742A/fr unknown
- 2019-09-27 BR BR112021005722A patent/BR112021005722A2/pt not_active Application Discontinuation
- 2019-09-27 TW TW108135110A patent/TW202028238A/zh unknown
- 2019-09-27 PE PE2021000378A patent/PE20211072A1/es unknown
- 2019-09-27 JP JP2021512587A patent/JP7519990B2/ja active Active
- 2019-09-27 EP EP19866533.3A patent/EP3856785A4/en active Pending
- 2019-09-27 CN CN201980076578.6A patent/CN113166247A/zh active Pending
- 2019-09-27 MX MX2021003608A patent/MX2021003608A/es unknown
- 2019-09-27 CR CR20210199A patent/CR20210199A/es unknown
- 2019-09-27 AU AU2019347412A patent/AU2019347412A1/en not_active Withdrawn
-
2021
- 2021-03-24 IL IL281787A patent/IL281787A/en unknown
- 2021-03-24 PH PH12021550662A patent/PH12021550662A1/en unknown
- 2021-03-25 CL CL2021000739A patent/CL2021000739A1/es unknown
- 2021-04-28 CO CONC2021/0005528A patent/CO2021005528A2/es unknown
-
2024
- 2024-05-23 JP JP2024083730A patent/JP7777183B2/ja active Active
-
2025
- 2025-11-14 JP JP2025194883A patent/JP2026021604A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7041516B2 (ja) | 共通軽鎖を有する二重特異性抗体又は抗体混合物 | |
| CN110431231B (zh) | 抗-cd3抗体和包含所述抗体的分子 | |
| IL272274B1 (en) | B7-h4 antibodies and methods of use thereof | |
| TW202208423A (zh) | Sars-cov-2抗體及其選擇和使用方法 | |
| KR20210137477A (ko) | 이중기능성 융합 단백질 및 그것의 제약학적 용도 | |
| JP7858629B2 (ja) | Fgfr3抗体および使用の方法 | |
| EP3359565A1 (en) | Anti-wt1/hla-specific antibodies | |
| JP2022533538A5 (cg-RX-API-DMAC7.html) | ||
| JP2020515277A5 (cg-RX-API-DMAC7.html) | ||
| JP2023133432A5 (cg-RX-API-DMAC7.html) | ||
| CA3210289A1 (en) | Mage-a4 peptide-mhc antigen binding proteins | |
| TW201134489A (en) | Basigin binding proteins | |
| JP2023542209A5 (cg-RX-API-DMAC7.html) | ||
| CN115515615A (zh) | Pilra抗体及其使用方法 | |
| CA3194641A1 (en) | Anti-tigit antibody, and pharmaceutical composition and use thereof | |
| KR102882299B1 (ko) | 항체 및 사용 방법 | |
| EP4637928A1 (en) | Antibodies targeting cd45 | |
| WO2021258337A1 (en) | Human monoclonal antibodies against tigit for immune related diseases | |
| JP2022505144A5 (cg-RX-API-DMAC7.html) | ||
| JP2020521752A (ja) | グロボhに対するヒト化抗体および癌治療におけるその使用 | |
| JP2025537255A (ja) | 抗アルファ5インテグリン抗体及びその使用 | |
| RU2021110931A (ru) | Антигенсвязывающие молекулы, обладающие способностью связываться с cd3 и cd137, но не одновременно | |
| US20240010730A1 (en) | Bispecific antibody and use thereof | |
| WO2022211629A1 (en) | Novel pd-1 binding domains | |
| WO2022100694A1 (zh) | 抗体及其制备方法 |